Group 1: Financial Performance - Company reported a revenue of 2.327 billion yuan for the first half of 2025, representing a 2.6% increase compared to 2.268 billion yuan in the same period last year [1] - Losses narrowed by 42.1% compared to the same period in 2024, with adjusted net losses reduced by 78.2% [1] - Improvement attributed to increased gross margin and optimized administrative expenses, indicating effective results from the company's smart transformation efforts [1] Group 2: Smart Pharmacy Initiatives - Company continues to invest in smart pharmacy construction, with the introduction of intelligent drug sorting and scanning devices [2] - These devices utilize machine vision technology and cloud computing, completing sorting and scanning of a single drug in under 10 seconds [2] - Nearly half of the orders are currently completed by smart devices, with plans for further increases in sorting efficiency [2] Group 3: "Xingyuan System" Capabilities - The proprietary "Xingyuan System" supports various subsystems, enhancing the smart pharmacy's operational capabilities [3] - The "Tianyan Zhizhi" feature optimizes site selection, expanding service range from 500 meters to 5 kilometers [3] - The use of robotic collaboration in four major intelligent warehouses has improved picking efficiency by 80% and reduced labor costs by 30% [3] Group 4: AI Technology in Service Optimization - Company has developed AI products such as Smart Little Dingdang, Health GPT, and AI consultation assistants to enhance user service efficiency [4] - Smart Little Dingdang can address over 80% of medication consultation queries using advanced models [4] - These technologies not only improve user experience but also help the company accumulate valuable data resources [4]